In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on Alexion Pharmaceuticals (ALXN), with a price target of $156. The company’s shares closed yesterday at $114.29.
According to TipRanks.com, Auster is a 3-star analyst with an average return of 6.2% and a 43.6% success rate. Auster covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Sarepta Therapeutics, and United Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alexion Pharmaceuticals with a $166.14 average price target, representing a 45.4% upside. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $140.77 and a one-year low of $92.56. Currently, Alexion Pharmaceuticals has an average volume of 1.79M.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma.
